Dr. Mason is Director of the Cancer Imaging Program at UT Southwestern with over 20 year's experience in cancer imaging, therapy, and tumor pathophysiology. He is Professor of Radiology and member of the Simmons Comprehensive Cancer Center. He serves on faculty of graduate programs in Biomedical Engineering, Molecular Biophysics and Cancer Biology. Dr. Mason and his research team have been supported for many years by NCI, DOD breast and prostate cancer initiatives, various foundations including The American Cancer Society, The Whitaker Foundation, and The Mary Kay Ash Foundation and most recently CPRIT. Dr. Mason’s primary research interest is prognostic radiology- developing and implementing methods for predicting optimal cancer therapy and assessing early response to treatment. Current investigations focus on development of oxygen sensitive MRI in pre-clinical breast, prostate and lung cancer as well as translation to human lung and prostate cancer. Dr. Mason is a recognized expert in the development of novel MR and optical reporter starategies with notable innovations in 19F NMR. Recent pre-clinical innovations include dynamic bioluminescent imaging related to vascular disputing agents and in vivo chemiluminescent imaging. Ongoing projects focus on novel vascular disrupting agents and assessment of pathophysiology of tumor response to therapy.
- University of Cambridge (1983), Natural Sciences
- Graduate School
- University of Cambridge (1986), Organic Chemistry
- Application of imaging methods to tumor development and response to therapy; development of NMR reporter molecules as probes of physiology and gene transfection; detoxification of xenobiotica; MR miscroscopy and tissue microstructure.
- Bioluminescent imaging
- gene therapy
- NMR- MRI
- Energy transfer chemiluminescence for ratiometric pH imaging.
- An W, Mason RP, Lippert AR Org. Biomol. Chem. 2018 May
- Tomographic breathing detection: a method to noninvasively assess in situ respiratory dynamics.
- O'Kelly D, Zhou H, Mason RP J Biomed Opt 2018 May 23 5 1-6
- Targeting Phosphatidylserine with Calcium-Dependent Protein-Drug Conjugates for the Treatment of Cancer.
- Li R, Chiguru S, Li L, Kim D, Velmurugan R, Kim D, Devanaboyina SC, Tian H, Schroit A, Mason RP, Ober RJ, Ward ES Mol. Cancer Ther. 2018 Jan 17 1 169-182
- MR-CBCT image-guided system for radiotherapy of orthotopic rat prostate tumors.
- Chiu TD, Arai TJ, Campbell Iii J, Jiang SB, Mason RP, Stojadinovic S PLoS ONE 2018 13 5 e0198065
- Oxygenation Imaging by Nuclear Magnetic Resonance Methods.
- Zhou H, Arias-Ramos N, López-Larrubia P, Mason RP, Cerdán S, Pacheco-Torres J Methods Mol. Biol. 2018 1718 297-313
- Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer.
- Zhou H, Hallac RR, Yuan Q, Ding Y, Zhang Z, Xie XJ, Francis F, Roehrborn CG, Sims RD, Costa DN, Raj GV, Mason RP Diagnostics (Basel) 2017 Aug 7 3
- Oxygen breathing challenge- the simplest theranostic.
- Mason RP Theranostics 2017 7 16 3873-3875
- Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization.
- Herdman CA, Strecker TE, Tanpure RP, Chen Z, Winters A, Gerberich J, Liu L, Hamel E, Mason RP, Chaplin DJ, Trawick ML, Pinney KG Medchemcomm 2016 Dec 7 12 2418-2427
- Carbon ion radiotherapy decreases the impact of tumor heterogeneity on radiation response in experimental prostate tumors.
- Glowa C, Karger CP, Brons S, Zhao D, Mason RP, Huber PE, Debus J, Peschke P Cancer Lett. 2016 Aug 378 2 97-103
- Effective Rat Lung Tumor Model for Stereotactic Body Radiation Therapy.
- Zhang Z, Wodzak M, Belzile O, Zhou H, Sishc B, Yan H, Stojadinovic S, Mason RP, Brekken RA, Chopra R, Story MD, Timmerman R, Saha D Radiat. Res. 2016 Jun 185 6 616-22
19F NMR: clinical and molecular imaging applications. In Fluorine in Pharmaceutical and Medicinal Chemistry: From Biophysical Aspects to Clinical Applications
V. D. Kodibagkar, R. Hallac, D. Zhao, J.-X. Yu, and R. P. Mason (2012). London, World Scientific Publishing Company
Non-Invasive Physiology and Pharmacology Using 19F Magnetic Resonance. In FLOURINE AND HEALTH
J.X. Yu, W. Cui, D. Zhao, and R. P. Mason (May 2008). Elsevier B.V.
Fluorocarbon Agents for Quantitative Multimodal Molecular Imaging and Targeted Therapeutics. In Molecular Imaging: Principles and Practice
S. A. Wickline, R. P. Mason, S. D. Caruthers, J. Chen, P. M. Winter, M. S. Hughes, G. M. Lanza (2010). People?s Medical Publishing House
MRI Hypoxia Measurements. In Functional Imaging in Oncology
S. Remmele, R. P. Mason, and J. P.B. O?Connor (2014). Heidelberg, Springer-Verlag
Innovative applications of reporter genes and gene reporters in prostate cancer. In Prostate Cancer Cells: Detection, Growth and Treatment
L. Liu, M. K. Alhasan, W. Cui, J. Magnusson, and R. P. Mason (2013). Hauppauge, NY, Nova Science Publishers
Honors & Awards
- Outstanding Teacher Award: International Society for Magnetic Resonance in Medicine (ISMRM), Honolulu, HI
Beyond Proton MRI: 19F MRI & More (2017)
- Outstanding Teacher Award: International Society for Magnetic Resonance in Medicine (ISMRM), Singapore
- Visiting Professor to the Hubei University of Medicine (HUM)
Famous Scientists Lecture Program in Hubei Province (2015-2015)
- Fellow of Royal Society of Chemistry
Chartered Scientist designation of the Science Council (2004)
- Lyndon Baines Johnson Award
American Heart Association (Texas Affiliate) (1993)
- Young Investigator Award at 5th International Society of Blood Substitutes Meeting
Presentation: Tumor oxygen tension: Measurement using OxygentTM as a 19F NMR probe at 4.7 T (1993)
Chartered Chemist of the Royal Society of Chemistry (1987)
- American Journal of Nuclear Medicine and Molecular Imaging (2011)
- Imaging in Medicine (2009)
- Letters in Drug Design & Discovery (2005)
- American Association for Cancer Research (1993)
- International Society of Magnetic Resonance in Medicine (1990)
- Royal Society of Chemistry (1987)